Simplicity Solutions LLC Grows Holdings in Hologic, Inc. (NASDAQ:HOLX)

Simplicity Solutions LLC raised its position in Hologic, Inc. (NASDAQ:HOLX) by 6.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,576 shares of the medical equipment provider’s stock after buying an additional 274 shares during the period. Simplicity Solutions LLC’s holdings in Hologic were worth $327,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Macquarie Group Ltd. increased its stake in shares of Hologic by 227.2% during the second quarter. Macquarie Group Ltd. now owns 6,284,053 shares of the medical equipment provider’s stock worth $435,485,000 after purchasing an additional 4,363,687 shares in the last quarter. Norges Bank purchased a new stake in shares of Hologic during the fourth quarter worth about $175,900,000. Arrowstreet Capital Limited Partnership increased its stake in shares of Hologic by 110.6% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,896,174 shares of the medical equipment provider’s stock worth $145,664,000 after purchasing an additional 995,854 shares in the last quarter. Qube Research & Technologies Ltd increased its stake in shares of Hologic by 117.2% during the third quarter. Qube Research & Technologies Ltd now owns 1,378,258 shares of the medical equipment provider’s stock worth $95,651,000 after purchasing an additional 743,557 shares in the last quarter. Finally, Prudential Financial Inc. increased its stake in shares of Hologic by 246.0% during the first quarter. Prudential Financial Inc. now owns 920,718 shares of the medical equipment provider’s stock worth $70,730,000 after purchasing an additional 654,628 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

NASDAQ:HOLX opened at $75.38 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18. The firm has a market capitalization of $17.69 billion, a price-to-earnings ratio of 35.73, a PEG ratio of 2.54 and a beta of 1.00. The company’s 50-day moving average is $75.75 and its two-hundred day moving average is $72.54. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $87.88.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.03. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. Hologic’s revenue was down 5.7% on a year-over-year basis. During the same period in the previous year, the business posted $1.07 EPS. Analysts forecast that Hologic, Inc. will post 4.01 EPS for the current year.

Insider Buying and Selling at Hologic

In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of the business’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the transaction, the director now directly owns 1,572 shares in the company, valued at approximately $119,802.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CFO Karleen Marie Oberton sold 14,940 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $75.00, for a total value of $1,120,500.00. Following the transaction, the chief financial officer now directly owns 103,916 shares in the company, valued at approximately $7,793,700. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Charles J. Dockendorff sold 1,465 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the transaction, the director now owns 1,572 shares in the company, valued at $119,802.12. The disclosure for this sale can be found here. Insiders have sold 32,846 shares of company stock worth $2,473,443 in the last ninety days. 1.75% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms have recently commented on HOLX. William Blair reissued an “outperform” rating on shares of Hologic in a research note on Friday, February 2nd. UBS Group boosted their target price on shares of Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a research note on Friday, February 2nd. Raymond James boosted their target price on shares of Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a research note on Friday, February 2nd. Needham & Company LLC restated a “buy” rating and set a $90.00 price target on shares of Hologic in a research report on Wednesday, April 10th. Finally, StockNews.com lowered shares of Hologic from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. Six equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $87.00.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.